A randomized parallel-group double-blind placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo both in combination with a glucocorticoid taper regimen i

Brief description of study

The purpose of this research study is to demonstrate if secukinumab 300 mg and secukinumab 150 mg administered as an injection under the skin is effective and safe in adult patients with newly diagnosed or relapsing giant cell arteritis (GCA).

Clinical Study Identifier: s21-00814
ClinicalTrials.gov Identifier: NCT04930094
Principal Investigator: David H. Goddard.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.